Bicycle Therapeutics plc - American Depositary Shares (BCYC)
BCYC moved a median of +0.02% 30 minutes after news, and +0.14% by the close. How BCYC actually reacts to news — the realized, point-in-time move the market made, measured across 534 labeled events over the last three years with zero look-ahead.
BCYC’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.07% | 51% | 503 |
| 30-min | +0.02% | 51% | 525 |
| 60-min | 0.00% | 51% | 525 |
| to close | +0.14% | 51% | 531 |
| Middle 50% of BCYC reactions | -0.71% to +1.08% |
|---|---|
| Median reaction (30-min) | +0.02% |
| Measured reactions | 534 |
Half of all Bicycle Therapeutics plc - American Depositary Shares news events land between -0.71% and +1.08% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How BCYC reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Rating reiterations | 83 | +0.35% | 55% | -0.60% |
| Price-target cuts | 21 | +0.50% | 62% | -0.60% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 3 further classes were observed with fewer than 10 measured events and are not published. See how BCYC ranks against every other measured name →
That’s how BCYC usually reacts — get an email when it moves on news →Email me when BCYC moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to BCYC's baseline. Nothing else.
Recent BCYC events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Prostate Cancer Foundation Expands Radiopharmaceutical Think Tank as Field Enters Pivotal Growth Phase | Press release | Business Wire | — | — | |
| Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2026 Financial Results | Press release | Business Wire | -0.91% | +3.89% | |
| Bicycle Therapeutics to Present Initial Duravelo-2 Data at 2026 ASCO Annual Meeting | Press release | Business Wire | +0.00% | +2.25% | |
| Hippocratic AI Expands Life Sciences Leadership Team as Pharma and Medtech Demand for Voice AI Agents Accelerates | Press release | PR Newswire | +0.00% | +0.23% | |
| TRIANA Biomedicines Announces the Appointment of Mohan Bala as Chief Operating Officer and Attracts Leading Experts to its Scientific Advisory Board | Press release | Business Wire | +1.12% | -2.24% | |
| William Blair Accelerates Investment in Biotech Equity Research and Equities Platform | Press release | Business Wire | -0.59% | -4.30% | |
| Bicycle Therapeutics Reports Recent Business Progress and First Quarter 2026 Financial Results | Press release | Business Wire | -0.32% | +1.29% | |
| Bicycle Therapeutics Announces Oral and Poster Presentations at the 2026 ASCO Annual Meeting | Press release | Business Wire | -0.58% | -4.83% | |
| Bicycle Therapeutics Provides Update on Nuzefatide Pevedotin and EphA2 Pipeline at the AACR Annual Meeting 2026 | Press release | Business Wire | -0.19% | +0.19% | |
| Orum Therapeutics Appoints Dr. Maria Koehler and Geoff Meyerson to Board of Directors | Press release | Business Wire | -1.01% | +0.81% | |
| Leerink Appoints Stephen Sands as Senior Advisor | Press release | PR Newswire | -0.43% | +0.43% | |
| Bicycle Therapeutics Announces Oral and Poster Presentations at the AACR Annual Meeting 2026 | Press release | Business Wire | -1.00% | -6.38% | |
| Bicycle Therapeutics Reports Recent Business Progress and Fourth Quarter and Full Year 2025 Financial Results | Press release | Business Wire | +1.76% | -0.78% | |
| Form 10-K BICYCLE THERAPEUTICS For: Dec 31 | SEC filing · Form 10-K | SEC EDGAR | +1.76% | -0.78% | |
| Form 8-K BICYCLE THERAPEUTICS For: Mar 17 | SEC filing · Form 8-K | SEC EDGAR | +1.76% | -0.78% | |
| Form S-8 BICYCLE THERAPEUTICS | SEC filing · Form S-8 | SEC EDGAR | -1.00% | -6.38% | |
| Bicycle Therapeutics Announces Leadership Transitions for Next Phase of Innovation Across Oncology Pipeline | Press release | Business Wire | +6.64% | -0.33% | |
| Form 8-K BICYCLE THERAPEUTICS For: Jan 29 | SEC filing · Form 8-K | SEC EDGAR | +6.64% | -0.33% | |
| Bicycle Therapeutics Highlights 2025 Accomplishments and Strategic Priorities for 2026 | Press release | Business Wire | -3.42% | -2.23% | |
| Form 8-K BICYCLE THERAPEUTICS For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -3.42% | -2.23% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Bicycle Therapeutics plc (BCYC) Shareholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.73% | -2.62% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Bicycle Therapeutics plc (BCYC) And Encourages Shareholders to Connect | Press release | ACCESS Newswire | +0.92% | -5.65% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bicycle Therapeutics plc (BCYC) And Encourages Shareholders to Reach Out | Press release | ACCESS Newswire | +0.16% | +3.83% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bicycle Therapeutics plc (BCYC) and Encourages Shareholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.07% | +0.15% | |
| Bicycle Therapeutics plc (BCYC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | +0.81% | -0.29% | |
| Bronstein, Gewirtz & Grossman, LLC Encourages Bicycle Therapeutics plc (BCYC) Stockholders to Inquire about Securities Investigation | Press release | ACCESS Newswire | +0.00% | -2.43% | |
| Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Bicycle Therapeutics plc (BCYC) And Encourages Stockholders to Reach Out | Press release | ACCESS Newswire | -0.14% | +1.99% | |
| Bronstein, Gewirtz & Grossman, LLC Is Investigating Bicycle Therapeutics plc (BCYC) And Encourages Stockholders to Connect | Press release | ACCESS Newswire | +0.14% | +4.20% | |
| Bicycle Therapeutics plc (BCYC) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation | Press release | ACCESS Newswire | -0.07% | +0.00% | |
| Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Bicycle Therapeutics plc (BCYC) and Encourages Stockholders to Learn More About the Investigation | Press release | ACCESS Newswire | -0.51% | -1.46% | |
| Bicycle Therapeutics Establishes Multiple Strategic Partnerships to Create End-to-End Supply Chain to Support its Wholly Owned Radiopharmaceutical Pipeline | Press release | Business Wire | -1.37% | +0.00% | |
| Ankyra Appoints Sailaja Battula, PhD as Chief Scientific Officer (CSO) | Press release | Business Wire | +0.00% | -1.61% | |
| Cassidy Bio Launches with the Goal to Develop Safer, More Scalable Gene Editing Therapies | Press release | Business Wire | +3.36% | -1.28% | |
| Bicycle Therapeutics to Participate in the Jefferies London Healthcare Conference | Press release | Business Wire | -0.23% | — | |
| Bicycle Therapeutics Reports Recent Business Progress and Third Quarter 2025 Financial Results | Press release | Business Wire | +2.32% | +7.09% | |
| Form 10-Q BICYCLE THERAPEUTICS For: Sep 30 | SEC filing · Form 10-Q | SEC EDGAR | +2.32% | +7.09% | |
| Form 8-K BICYCLE THERAPEUTICS For: Oct 30 | SEC filing · Form 8-K | SEC EDGAR | +2.32% | +7.09% | |
| Form S-8 BICYCLE THERAPEUTICS | SEC filing · Form S-8 | SEC EDGAR | +0.73% | -1.94% | |
| HPV-Positive Oropharyngeal Cancer Market Poised for Strong Growth by 2034, Driven by Rising Incidence and Treatment Innovation | DelveInsight | Press release | PR Newswire | +1.04% | +8.04% | |
| Bicycle Therapeutics Strengthens Board of Directors with New Appointments | Press release | Business Wire | +1.35% | +1.57% | |
| Form 8-K BICYCLE THERAPEUTICS For: Sep 08 | SEC filing · Form 8-K | SEC EDGAR | +1.35% | +1.57% | |
| Maxion Therapeutics Strengthens Board with Appointment of Dr. Santiago Arroyo as a Non-Executive Director | Press release | GlobeNewswire | +0.00% | +0.57% | |
| Form EFFECT BICYCLE THERAPEUTICS | SEC filing · Form EFFECT | SEC EDGAR | +0.00% | +0.68% | |
| Bicycle Therapeutics Reports Recent Business Progress and Second Quarter 2025 Financial Results | Press release | Business Wire | +5.17% | +1.32% | |
| Form 10-Q BICYCLE THERAPEUTICS For: Jun 30 | SEC filing · Form 10-Q | SEC EDGAR | +5.17% | +1.32% | |
| Form 8-K BICYCLE THERAPEUTICS For: Aug 06 | SEC filing · Form 8-K | SEC EDGAR | +5.17% | +1.32% | |
| Form S-3 BICYCLE THERAPEUTICS | SEC filing · Form S-3 | SEC EDGAR | -2.58% | -3.74% | |
| Urothelial Carcinoma Market Set to Expand During the Forecast Period (2025-2034) Amid Rising Incidence and Evolving Therapeutic Landscape | DelveInsight | Press release | PR Newswire | +0.80% | -1.06% | |
| Bicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | Press release | Business Wire | -0.13% | -0.13% | |
| Form 8-K BICYCLE THERAPEUTICS For: Jun 17 | SEC filing · Form 8-K | SEC EDGAR | +2.29% | -2.88% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the BCYC section they belong to.
Where else BCYC is measured.
BCYC earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Bicycle Therapeutics plc - American Depositary Shares's median reaction calculated?
Every labeled BCYC news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 534 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 51% of BCYC's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does BCYC's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.